The BNTM II system from Siemens Healthineers is a nephelometric analyzer that complements MLM’s excellent lab device portfolio, in the field of protein analysis. With more than 65 assay protocols available the BNTM II can automatically process’ serum, plasma, urine, CSF and STAT samples. Innovative markers include monoclonal kappa and lambda free light chains (FLC), cystatin C, beta-trace protein (BTP) and carbohydrate-deficient transferrin (CDT). With its broad assay portfolio the BNTM II is another valuable lab device, especially for clinical trials in the fields of kidney disease, polyclonal and monoclonal gammopathies, cardiovascular disease and neurology.
The BNTM II expands MLM’s assay portfolio which covers more than 300 validated parameters.
The current assay portfolio is also available online and delivers valuable extra information, e.g. stability, about the parameter.
If you have any questions about our assay portfolio or any other services, please contact Isabel Struik, VP Sales & Marketing, email@example.com.